Company profile
ARS Pharmaceuticals, Inc.
NASDAQ: SPRY · Healthcare · Biotechnology
#368 of 1,418 Healthcare companies by revenue35th-percentile growth
EA Score
41DFH 43DQ 31GM 44SS 58
v0.1 · 65/100 weight · provisional
↑ 3-yr revenue growth, market scale · ↓ growth stability, disclosure history
Methodology →Revenue TTM
$99.0M
Rev growth YoY (TTM)
+1.9%
Net income (FY)
-$171.3M
Employees
157
as of 2026-08-10
Market cap
$611.7M
as of 2026-08-10
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$84.3M$84.3M2025
Net income-$171.3M-$171.3M2025
Operating income-$179.4M-$179.4M2025
Total assets$327.7M$327.7M2025
Liabilities$213.4M$213.4M2025
Equity$114.3M$114.3M2025
Revenue trend
FY2022 – FY2025 · USD
FY22
FY22
FY23
FY24
FY25
Revenue by segment
Filed disclosures · FY2025
By product
Product100%
By geography
UNITED STATES86%
Non-US14%
The read
What is ARS Pharmaceuticals, Inc.’s revenue?
ARS Pharmaceuticals, Inc. booked $84.3M in FY2025 revenue, contracting 5.5% year over year — slower than 65% of Healthcare companies we track, at a -203.3% net margin.
Peers · Healthcare
Standard BioTools Inc.61CDelcath Systems, Inc.72B4D Molecular Therapeutics, Inc.58CNurix Therapeutics, Inc.53DIRadimed Corporation86AArcturus Therapeutics Holdings Inc.49DNeighbors
San Diego →Key facts
CEODonn Casale
SectorHealthcare
IndustryBiotechnology
HeadquartersSan Diego, CA
ExchangeNASDAQ: SPRY
Employees157
IPO date2020-12-04
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.